Amedisys (AMED) Stock Forecast & Price Target

$97.25

-0.05 (-0.05%)

(As of 07/5/2024 08:52 PM ET)

Amedisys - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 5 Analyst Ratings

Consensus Price Target

$100.67
3.51% Upside

High Forecast	$101.00
Average Forecast	$100.67
Low Forecast	$100.00

Type	Current Forecast 7/9/23 to 7/8/24	1 Month Ago 6/9/23 to 6/8/24	3 Months Ago 4/10/23 to 4/9/24	1 Year Ago 7/9/22 to 7/9/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	3 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	7 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$100.67	$100.80	$97.50	$110.21
Forecasted Upside	3.51% Upside	10.48% Upside	7.47% Upside	22.56% Upside

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

AMED Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMED Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amedisys Stock vs. The Competition

Type	Amedisys	Medical Companies	S&P 500
Consensus Rating Score	2.20	2.71	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	3.51% Upside	1,005.50% Upside	12.25% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Larew Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
4/25/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$101.00	+10.99%
3/26/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform
3/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$97.00 ➝ $100.00	+8.52%
7/31/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$84.00 ➝ $101.00	+11.22%
7/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
Obama wins Presidential debate (Ad) When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” Please, watch this now before it’s too late.
6/27/2023	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
6/27/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$97.00 ➝ $101.00	+10.99%
6/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$88.00 ➝ $101.00	+10.99%
6/6/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$96.00 ➝ $81.00	+1.30%
3/14/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight	$103.00	+30.43%
1/19/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$145.00 ➝ $125.00	+34.12%
1/5/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform	$96.00 ➝ $85.00	-1.16%
11/4/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$88.00	+1.77%
11/4/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$103.00	+19.12%
10/24/2022	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$175.00 ➝ $165.00	+72.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:25 AM ET.

AMED Forecast - Frequently Asked Questions

What is Amedisys' forecast for 2024?: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Amedisys is $100.67, with a high forecast of $101.00 and a low forecast of $100.00.
Should I buy or sell Amedisys stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
Does Amedisys's stock price have much upside?: According to analysts, Amedisys's stock has a predicted upside of 10.24% based on their 12-month stock forecasts.
Has Amedisys been downgraded by Wall Street analysts recently?: Over the previous 90 days, Amedisys's stock had 1 downgrade by analysts.
What analysts cover Amedisys?: Amedisys has been rated by research analysts at Cantor Fitzgerald, and William Blair in the past 90 days.
Do Wall Street analysts like Amedisys more than its competitors?: Analysts like Amedisys less than other "medical" companies. The consensus rating for Amedisys is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMED compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:AMED) was last updated on 7/8/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Amedisys (AMED) Stock Forecast & Price Target

Amedisys - Analysts' Recommendations and Stock Price Forecast (2024)

Consensus Rating

Consensus Price Target

AMED Analyst Recommendations By Month

AMED Price Targets by Month

Amedisys Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

AMED Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amedisys (AMED) Stock Forecast & Price Target

Amedisys - Analysts' Recommendations and Stock Price Forecast (2024)

Consensus Rating

Consensus Price Target

AMED Analyst Recommendations By Month

AMED Price Targets by Month

Amedisys Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

AMED Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools